Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel L Suzman

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
Clinical Trials (London, England)|March 11, 2020
Exploration of baseline patient-reported side effect bother from cancer therapyJessica K Roydhouse, Bellinda L King-Kallimanis, Pourab Roy, et al.
JAMA Oncology|September 13, 2019
Global Variation in Opioid Use in Prostate Cancer TrialsJessica K Roydhouse, Daniel L Suzman, Laurel A Menapace, et al.
AIDS (London, England)|July 11, 2008
Identification of novel markers for liver fibrosis in HIV/hepatitis C virus coinfected individuals using genomics-based approachDaniel L Suzman, Mary McLaughlin, Zonghui Hu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 15, 2020
An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate CancerMichael Brave, Chana Weinstock, Jamie R Brewer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 14, 2024
Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled AnalysisJaleh Fallah, Jianjin Xu, Chana Weinstock, et al.
Cancer Chemotherapy and Pharmacology|November 10, 2016
Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancerBenjamin L Maughan, Daniel L Suzman, Brandon Luber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 9, 2024
FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell CarcinomaJaleh Fallah, Brian L Heiss, Hee-Koung Joeng, et al.
The Oncologist|December 14, 2018
FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing ChemotherapyDaniel L Suzman, Sundeep Agrawal, Yang-Min Ning, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2024
Equipoise Lost? Trial Conduct Challenges in an Era of Breakthrough TherapiesJaleh Fallah, Flora Mulkey, Mallorie H Fiero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2024
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial CarcinomaWilliam F Maguire, Daniel Lee, Chana Weinstock, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Clinical Trials (London, England)|March 11, 2020
Exploration of baseline patient-reported side effect bother from cancer therapyJessica K Roydhouse, Bellinda L King-Kallimanis, Pourab Roy, et al.
JAMA Oncology|September 13, 2019
Global Variation in Opioid Use in Prostate Cancer TrialsJessica K Roydhouse, Daniel L Suzman, Laurel A Menapace, et al.
AIDS (London, England)|July 11, 2008
Identification of novel markers for liver fibrosis in HIV/hepatitis C virus coinfected individuals using genomics-based approachDaniel L Suzman, Mary McLaughlin, Zonghui Hu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 15, 2020
An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate CancerMichael Brave, Chana Weinstock, Jamie R Brewer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 14, 2024
Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled AnalysisJaleh Fallah, Jianjin Xu, Chana Weinstock, et al.
Cancer Chemotherapy and Pharmacology|November 10, 2016
Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancerBenjamin L Maughan, Daniel L Suzman, Brandon Luber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 9, 2024
FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell CarcinomaJaleh Fallah, Brian L Heiss, Hee-Koung Joeng, et al.
The Oncologist|December 14, 2018
FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing ChemotherapyDaniel L Suzman, Sundeep Agrawal, Yang-Min Ning, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2024
Equipoise Lost? Trial Conduct Challenges in an Era of Breakthrough TherapiesJaleh Fallah, Flora Mulkey, Mallorie H Fiero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2024
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial CarcinomaWilliam F Maguire, Daniel Lee, Chana Weinstock, et al.
Pageof 5